Skip to main content

Valsartan Cases Stayed Until The Next Case Management Order

Valsartan Cases Stayed Until The Next Case Management Order

Valsartan Cases Stayed Until The Next Case Management Order

Introduction

U.S. District Judge Robert B. Kugler, presiding over all federal valsartan lawsuits, issued an order on February 25, to stay all pending deadlines entered in these cases before the valsartan multidistrict litigation (MDL) was established. The stay will remain effective until any further orders are issued at the end of an initial case management conference scheduled for March 27.

The stay request was filed by generic drug makers to suspend or vacate all deadlines established before the formation of the federal MDL. The product liability claims and class actions filed against the drug makers alleged that the generic versions of the hypertension medicine contained cancer-causing chemicals, including N-nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA). The complaints also involved claims that the patients were diagnosed with liver cancer, kidney cancer, bladder cancer, stomach cancer, and other digestive tract cancers due to the consumption of tainted medicines.

If the manufacturers are unsuccessful in reaching on a settlement agreement or resolution for the litigation, individual cases might be remanded back to the U.S. District Court for a future trial date.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients

A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…

FDA Adds New Warnings on Long-Term Opioid Risks

Categories: Opioids

Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!